CTA submitted in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101) for Solid Tumors
“Submitting our first CTA is a transformational moment for Zelluna,” said Namir Hassan, Chief Executive Officer of Zelluna. “ZI-MA4-1 will be the first MAGE-A4-targeting TCR-NK cell therapy to enter clinical testing globally and represents the culmination of rigorous scientific, non-clinical, CMC and regulatory work. Reaching this major milestone is a testament to the unwavering dedication and talent of the Zelluna team past and present, the guidance of our board, and the commitment of our investors. I am immensely proud of our team for delivering on the commitments we set out to achieve this year. We now enter the most important phase of our journey – demonstrating the potential of TCR-NK therapies for solid cancer patients.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo